1. Angiotensin receptor (AT2R) agonist C21 prevents cognitive decline after permanent stroke in aged animals—A randomized double- blind pre-clinical study
- Author
-
Susan C. Fagan, Almira Vazdarjanova, Jennifer L. Waller, Tauheed Ishrat, Bindu Pillai, Kristopher M. Bunting, Heba A. Ahmed, and Adviye Ergul
- Subjects
Male ,Agonist ,Aging ,Angiotensin receptor ,Time Factors ,medicine.drug_class ,Drug Evaluation, Preclinical ,Administration, Oral ,Thiophenes ,Motor Activity ,Receptor, Angiotensin, Type 2 ,Article ,Clinical study ,Double blind ,Random Allocation ,03 medical and health sciences ,Behavioral Neuroscience ,0302 clinical medicine ,Double-Blind Method ,Animals ,Medicine ,Cognitive Dysfunction ,Rats, Wistar ,Cognitive decline ,Stroke ,Nootropic Agents ,030304 developmental biology ,Sulfonamides ,0303 health sciences ,business.industry ,Body Weight ,Cognition ,Recovery of Function ,medicine.disease ,Disease Models, Animal ,Anesthesia ,business ,Complication ,030217 neurology & neurosurgery - Abstract
Post stroke cognitive impairment (PSCI) is an understudied, long-term complication of stroke, impacting nearly 30-40% of all stroke survivors. No cure is available once the cognitive deterioration manifests. To our knowledge, this is the first study to investigate the long-term effects of C21 treatment on the development of PSCI in aged animals. Treatments with C21 or vehicle were administered orally, 24 h post-stroke, and continued for 30 days. Outcome measures for sensorimotor and cognitive function were performed using a sequence of tests, all blindly conducted and assessed at baseline as well as at different time points post-stroke. Our findings demonstrate that the angiotensin receptor (AT2R) agonist C21 effectively prevents the development of PSCI in aged animals.
- Published
- 2019
- Full Text
- View/download PDF